Premium
Combination of aminophylline (Phyllocontin Continus tablets) and salbutamol in the management of chronic obstructive airways disease.
Author(s) -
Clark CJ,
Boyd G
Publication year - 1980
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1980.tb01062.x
Subject(s) - aminophylline , salbutamol , medicine , bronchodilator , pulmonary disease , bronchodilator agents , asthma , anesthesia , cardiology
1 The effect of a controlled release theophylline derivative (Phyllocontin Continus tablets) and an adrenoceptor agonist (salbutamol) was compared when taken singly and concomitantly in twenty patients with chronic bronchitis and additional reversible airways obstruction using a double‐blind crossover technique. 2 The pulmonary function data showed a significant improvement in airways obstruction with an associated reduction in hyperinflation on combination therapy, as compared with either drug taken alone. 3 No significant improvement in patient symptoms occurred on combination therapy as compared with either drug taken alone. 4 A high incidence of side‐effects was noted with both Phyllocontin Continus and salbutamol. Combination therapy, however, did not increase the frequency or severity of side‐effects seen on either drug alone. 5 Although a proportion of patients showed evidence of intercurrent infection during the nine‐week trial period, this did not appear to influence the results for the group as a whole.